VC-backed Homology Medicines goes public
Bedford, Massachusetts-based Homology Medicines Inc, a genetic medicines company, has raised $144 million for its IPO after pricing its 9 million shares at $16 per share. The stock began trading March 28, 2018 on the NASDAQ under the ticker symbol "FIXX." BofA Merrill Lynch, Cowen and Evercore ISI are the lead underwriters. Homology's pre-IPO backers include Deerfield Management, Fidelity Management and Research Company, HBM Healthcare Investments, Maverick Ventures, Novartis, Rock Springs Capital, Vida Ventures, Vivo Capital, Alexandria Venture Investments, 5AM Ventures, ARCH Venture Partners and Temasek.
28 March 2018•2 mins read
